AI assistant
UroGen Pharma Ltd. — Director's Dealing 2022
Feb 2, 2022
32312_dirs_2022-02-02_a2447de1-2c80-4127-a563-f86290de4b8b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-01-31
Reporting Person: Henderson Molly (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-31 | Ordinary Shares | M | 666 | — | Acquired | 5579 | Direct |
| 2022-01-31 | Ordinary Shares | S | 331 | $7.58 | Disposed | 5248 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-31 | Restricted Stock Units | $ | M | 666 | Disposed | Ordinary Shares (1334) | Direct | |
| 2022-01-31 | Restricted Stock Units | $ | A | 7500 | Acquired | Ordinary Shares (7500) | Direct | |
| 2022-01-31 | Stock Option (right to buy) | $7.72 | A | 30000 | Acquired | 2032-01-31 | Ordinary Shares (30000) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3: The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
F4: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.
F5: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.